Alterity Therapeutics Ltd. has released a press release.
Granted New U.S. Composition of Matter Patent for ATH434
Earlier from Alterity Therapeutics
- Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
- ATH Receives A$3.98m R&D Tax Incentive
- Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy